| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $0 | — | — |
| R&D Expense | $5.1M | — | +60.0% |
| SG&A Expense | $4.1M | — | +44.3% |
| Operating Income | -$9.3M | — | -52.6% |
| Net Income | -$8.4M | — | -44.6% |
| EPS (Basic) | -$0.05 | — | +28.6% |
| EPS (Diluted) | -$0.05 | — | +28.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $107.1M | +49.2% | +277.1% |
| Current Assets | $111.2M | +47.8% | +247.7% |
| Total Assets | $114.2M | +45.7% | +226.6% |
| Current Liabilities | $6.5M | -8.0% | -6.3% |
| Total Liabilities | $6.8M | -9.5% | -6.0% |
| Stockholders' Equity | $107.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.8M | — | +2.5% |
| Financing Cash Flow | $44.1M | — | +87.2% |
| +286.9% |